Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas

Modern Pathology

Volumn 23, Issue 7, 2010, Pages 909-920

  Seegmiller, Adam C ^a   Garcia, Rolando ^a   Huang, Rong ^a   Maleki, Atousa ^a   Karandikar, Nitin J ^a   Chen, Weina ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma with features between Burkitt lymphoma and diffuse large B cell lymphoma; Burkitt lymphoma; diffuse large B cell lymphoma; IG MYC rearrangement; karyotype; plasmablastic lymphoma

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL 6; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; MYC PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER SURVIVAL; CHILD; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; KARYOTYPE; LARGE CELL LYMPHOMA; MALE; ONCOGENE MYC; OVERALL SURVIVAL; PLASMABLASTIC LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; BIOSYNTHESIS; CELL SEPARATION; CHROMOSOME ABERRATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BURKITT LYMPHOMA; CELL SEPARATION; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; YOUNG ADULT;

EID: 77954243397     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.76     Document Type: Article

References (31)

1. Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization Classification of Tumors of Haematopoieitc and Lymphoid Tissues 2008, WHO Press: Geneva, Switzerland, pp 262-264.
2. Cogliatti SB, Novak U, Henz S, et al. Diagnosis of Burkitt lymphoma in due time: a practical approach. Br J Haematol 2006;134:294-301.
3. Haralambieva E, Boerma EJ, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005;29:1086-1094.
4. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 2005;29:1652-1660.
5. Rodig SJ, Vergilio JA, Shahsafaei A, et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol 2008;32:113-122.
6. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006;19:25-33.
7. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a southwest oncology group study delineating phenotypic, genotypic, and clinical features. Blood 2001;97:3713-3720.
8. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with feature intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J Vardiman JW (eds). World Health Organization Classification of Tumors of Haemato-poieitc and Lymphoid Tissues 2008, WHO Press: Geneva, Switzerland, pp 265-266.
9. Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 2006;107:1084-1092.
10. Lones MA, Sanger WG, Le Beau MM, et al. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol 2004;26:169-178.
11. Poirel HA, Cairo MS, Heerema NA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 International Study. Leukemia 2009;23:323-331.
12. Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000;18:574-583.
13. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354: 2431-2442.
14. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-2430.
15. Xu Y, McKenna RW, Doolittle JE, et al. The t(14;18) in diffuse large B-cell lymphoma: correlation with germinal center-associated markers and clinical features. Appl Immunohistochem Mol Morphol 2005;13:116-123.
16. Chen W, Asplund SL, McKenna RW, et al. Characterization of incidentally identified minute clonal B-lymphocyte populations in peripheral blood and bone marrow. Am J Clin Pathol 2004;122:588-595.
17. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature. S Karger: Basel, 2005.
18. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization Classification of Tumors of Haematopoieitc and Lymphoid Tissues 2008, pp 256-257.
19. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swer-dlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization Classification of Tumors of Haematopoieitc and Lymphoid Tissues 2008, p. 233-237.
20. Maleki A, Seegmiller AC, Uddin N, et al. Bright CD38 expression is an indicator of MYC rearrangement. Leuk Lymphoma 2009;50:1054-1057.
21. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 Ann Oncol 1999;10: 1419-1432.
22. Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008;216:440-450.
23. Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytoge-netics in the light of todays knowledge. Leukemia 2009;23:225-234.
24. Johnson NA, Savage KJ, Ludkovski O, et al. Lympho-mas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273-22799.
25. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene re-arrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.
26. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152-3162.
27. Ladanyi M, Offit K, Jhanwar SC, et al. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991;77:1057-1063.
28. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasma-blastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Path 2009;132:597-605.
29. Akasaka T, Akasaka H, Ueda C, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000;18:510-518.
30. Salaverria I, Zettl A, Bea S, et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica 2008;93:1327-1334.
31. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular profiling of pediatric mature B-cell lympho-ma treated in population-based prospective clinical trials. Blood 2008;112:1374-1381.